

RESEARCH MONOGRAPH . COMPOUND PROFILE

Nebivolol

A highly beta-1 selective adrenergic receptor antagonist distinguished from all other marketed beta-blockers by endothelial nitric oxide-dependent vasodilation mediated through beta-3 adrenergic receptor agonism and GRK/beta-arrestin biased signaling, conferring hemodynamic, metabolic, and tolerability advantages in hypertension and heart failure.

DOCUMENT	KDC-MN-1558
ISSUED	2026-05-20
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	Third-generation beta-1 selective adrenergic receptor antagonist with nitric oxide-mediated vasodilatory activity

ABSTRACT

Nebivolol is a third-generation beta-adrenergic receptor antagonist with the highest beta-1 selectivity among clinically available beta-blockers and a unique vasodilatory mechanism mediated by endothelial nitric oxide (NO) release. The compound was patented by Janssen Pharmaceutica in 1983, entered clinical use in Europe in 1997, and received United States Food and Drug Administration approval in December 2007 for the treatment of hypertension, marketed as Bystolic by Forest Laboratories (now Allergan/AbbVie). Nebivolol is a racemic mixture of equal proportions of d-nebivolol (SRRR configuration) and l-nebivolol (RSSS configuration), each containing four stereocenters within a bis-chromanol scaffold linked by an aminoethanol bridge. The d-enantiomer carries the beta-1 adrenergic antagonist activity, while the l-enantiomer predominantly mediates nitric oxide release through beta-3 adrenergic receptor agonism and activation of endothelial nitric oxide synthase (eNOS) via serine-1177 phosphorylation. This dual mechanism produces a hemodynamic profile that combines heart rate reduction and negative inotropy (classical beta-blockade) with peripheral vasodilation and reduced systemic vascular resistance (NO-mediated), distinguishing nebivolol from older beta-blockers that increase or fail to reduce peripheral resistance.

The pharmacokinetic profile is dominated by extensive hepatic metabolism through cytochrome P450 2D6 (CYP2D6), producing a striking polymorphic phenotype: oral bioavailability is approximately 12 percent in extensive metabolizers and rises to approximately 96 percent in poor metabolizers. The plasma

elimination half-life of d-nebivolol is approximately 12 hours in extensive metabolizers and approximately 19 hours in poor metabolizers. Steady-state plasma concentrations in poor metabolizers are 10- to 15-fold higher than in extensive metabolizers at equivalent doses. The CYP2D6 dependence has direct clinical implications for dose adjustment, drug-drug interactions with CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine), and inter-individual variability in blood pressure response.

The principal clinical evidence base comprises the SENIORS trial (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure), which randomized 2128 elderly patients (age 70 years or older) with symptomatic heart failure to nebivolol or placebo and demonstrated a significant reduction in the composite primary endpoint of all-cause mortality or cardiovascular hospital admission (hazard ratio 0.86, 95 percent confidence interval 0.74 to 0.99, $P = 0.039$). Multiple randomized controlled trials in hypertension have demonstrated blood pressure reductions comparable to or exceeding those of other beta-blockers, with superior tolerability including significantly lower rates of fatigue, sexual dysfunction, and metabolic derangement (glucose and lipid abnormalities). Preclinical evidence demonstrates cardioprotective, antioxidant, and anti-inflammatory properties mediated through beta-3 receptor stimulation, NLRP3 inflammasome suppression, and mitochondrial biogenesis enhancement.

This monograph reviews the chemistry, stereochemistry, and synthesis of nebivolol; the dual beta-1 antagonist and NO-mediated vasodilatory mechanism in molecular detail; the

comprehensive human pharmacokinetic record including CYP2D6 polymorphism; preclinical pharmacology across cardiovascular, metabolic, and inflammatory models; the clinical evidence base in hypertension and heart failure; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event profile; and a comparative assessment of five alternative beta-blockers (metoprolol, bisoprolol, carvedilol, atenolol, propranolol) against nebivolol on five competency standards (novelty, effect size, tolerability profile, metabolic neutrality, and overall validation).

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Nebivolol.

Marketed names: Bystolic (AbbVie/Allergan, United States), Nebilet (Menarini, European Union), Nebilox (generic markets), Nodon (select European markets), Lobivon (Germany), Temerit (France), Nebispes (generic).

Development codes: R 65824 (Janssen Pharmaceutica). The Janssen development code is the canonical identifier in the early patent and pharmacology literature.

Chemical Abstracts Service registry numbers: 99200-09-6 (racemic free base), 152520-56-4 (hydrochloride salt). The racemic form is the clinically administered material; the individual enantiomers are designated as (+)-nebivolol (d-nebivolol, SRRR) and (-)-nebivolol (l-nebivolol, RSSS).

International Union of Pure and Applied Chemistry name: 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol. The compound consists of two 6-fluoro-2H-chromanol (6-fluorochroman-2-yl) ring systems linked through an aminoethanol bridge bearing two secondary hydroxyl groups.

1.2 Structural class and chemistry

Nebivolol is a bis-chromanol beta-adrenergic receptor ligand distinguished from all other marketed beta-blockers by the incorporation of two fused benzopyran (chromanol) ring systems rather than the single aryloxypropanolamine pharmacophore common to propranolol, metoprolol, atenolol, bisoprolol, and carvedilol. The increased rigidity of the chromanol ring structures constrains the three-dimensional geometry of the molecule and is proposed to underlie the exceptionally high beta-1 selectivity (approximately 321-fold selectivity for beta-1 over beta-2 adrenergic receptors, the highest among clinically available beta-blockers) [1].

Molecular formula: C₂₂H₂₅F₂NO₄ (free base); C₂₂H₂₆ClF₂NO₄ (hydrochloride salt).

Exact mass: 405.1752 g/mol (free base, monoisotopic).

Molecular weight: 405.44 g/mol (free base); 441.90 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. Soluble in methanol and dimethyl sulfoxide; sparingly soluble in water (as the free base); freely soluble in acidic aqueous media as the hydrochloride salt. Melting point of the hydrochloride salt is approximately 228 to 232 degrees Celsius. The compound is photostable under normal handling conditions.

Stereochemistry: Nebivolol contains four stereocenters (two within each chromanol ring and two at the hydroxyl-bearing carbons of the aminoethanol bridge). The molecule's internal symmetry reduces the theoretical 16 stereoisomers to 10 distinct forms. The marketed product is a racemic mixture (1:1) of the SRRR (d-nebivolol, dextrorotatory) and RSSS (l-nebivolol, levorotatory) enantiomers. Notably, nebivolol departs from the standard beta-blocker pharmacophore model in that its cardiac antihypertensive activity resides in the d-enantiomer (R-configuration at the hydroxyl-bearing carbon proximal to the amine), whereas all other marketed beta-blockers carry antihypertensive activity in the S-enantiomer [2]. The l-enantiomer is principally responsible for the vasodilatory, NO-releasing activity through beta-3 adrenergic receptor agonism. Investigators acquiring research-grade nebivolol should confirm enantiomeric composition by chiral high-performance liquid chromatography, as the racemic mixture is the clinically active form and individual enantiomers produce pharmacologically distinct profiles.

1.3 Synthesis

The synthesis of nebivolol proceeds through the construction of two 6-fluorochromanol subunits followed by coupling through the central aminoethanol linker. The principal route begins with 2-chloro-1-(6-fluorochroman-2-yl)ethanone as a key intermediate, prepared from 6-fluorochromanol by Friedel-Crafts acylation or by ring-opening/cyclization strategies. The two chromanol subunits are joined through reductive amination of the respective chloroketone and amino alcohol intermediates, followed by stereoselective reduction of the ketone functionality to establish the secondary hydroxyl groups [3]. Industrial syntheses employ chiral resolution (classical diastereomeric salt formation or chiral chromatography) to obtain the desired SRRR/RSSS racemic pair from the mixture of stereoisomers produced during synthesis. Recent enzymatic approaches using lipase-catalyzed asymmetric desymmetrization have been reported for enantiopure (+)-nebivolol preparation

[4]. The hydrochloride salt is prepared by treatment with hydrogen chloride in a suitable solvent (diethyl ether, ethanol) followed by recrystallization. Industrial-scale synthesis typically achieves greater than 99 percent chemical purity and the correct racemic enantiomeric composition (1:1 SRRR:RSSS) as confirmed by chiral HPLC.

2. Abstract

Nebivolol (R 65824) is a third-generation, highly beta-1 selective adrenergic receptor antagonist that combines classical cardiac beta-blockade with endothelium-dependent vasodilation mediated through nitric oxide release, a pharmacological profile unique among marketed beta-blockers [1, 5]. The compound was developed by Janssen Pharmaceutica (Belgium), patented in 1983, and entered clinical use in multiple European jurisdictions beginning in 1997. The United States Food and Drug Administration approved nebivolol hydrochloride tablets (Bystolic) for the treatment of hypertension in December 2007, on the basis of a clinical trial program involving more than 2000 patients demonstrating significant reductions in systolic and diastolic blood pressure across diverse patient populations [6].

The dual mechanism of action is the defining pharmacological characteristic. The d-enantiomer (SRRR) produces highly selective beta-1 adrenergic receptor antagonism with approximately 321-fold selectivity over beta-2 receptors, reducing heart rate, cardiac contractility, and myocardial oxygen demand through classical beta-blockade. The l-enantiomer (RSSS) stimulates endothelial nitric oxide synthase (eNOS) through beta-3 adrenergic receptor agonism, producing serine-1177 phosphorylation of eNOS, increased NO bioavailability, and consequent vasodilation of resistance and conductance arteries [7, 8]. A third mechanistic layer was identified by Erickson et al. (2013), who demonstrated that nebivolol functions as a GRK/beta-arrestin biased agonist at beta-1 and beta-2 adrenergic receptors, producing receptor internalization and beta-arrestin-dependent ERK1/2 signaling without classical G-protein-coupled cAMP generation [9]. This biased agonism provides a molecular framework for the cardioprotective and anti-inflammatory properties observed in preclinical models that are not explained by classical beta-blockade or NO release alone.

The SENIORS trial (Flather et al. 2005), the largest outcomes trial for nebivolol, randomized 2128 patients aged 70 years or older with clinical heart failure to nebivolol (target dose 10 mg daily) or placebo [10]. After a mean follow-up of 21 months, nebivolol significantly reduced the composite primary endpoint of all-cause mortality or cardiovascular hospital admission (31.1 percent versus 35.3 percent; hazard ratio 0.86, 95 percent CI 0.74 to 0.99, $P = 0.039$). The effect was consistent across subgroups defined by age, sex, and ejection fraction, though all-cause

mortality alone did not reach statistical significance (15.8 percent versus 18.1 percent, $P = 0.21$). Meta-analyses of randomized controlled trials in hypertension have demonstrated blood pressure reductions of approximately 11 mmHg systolic and 8 mmHg diastolic at standard doses, with a tolerability profile significantly superior to older beta-blockers including lower rates of fatigue, sexual dysfunction, bronchospasm, and metabolic derangement [11, 12].

Pharmacokinetics are dominated by CYP2D6 hepatic metabolism, producing a dramatic polymorphic phenotype with 8-fold variation in bioavailability between extensive and poor metabolizers [13, 14]. The compound is supplied as oral tablets in 2.5, 5, 10, and 20 mg strengths for clinical use and as research-grade material from multiple chemical suppliers for investigational applications. This monograph documents the complete pharmacological, pharmacokinetic, and clinical profile of nebivolol as a research compound and clinical agent.

3. Discovery and Development History

3.1 Origin

Nebivolol was synthesized at Janssen Pharmaceutica N.V. (Beerse, Belgium) in the early 1980s as part of a medicinal chemistry program exploring chromanol-based structures as beta-adrenergic receptor ligands. The compound was patented in 1983 under patent number BE 897 203. The design rationale departed from the aryloxypropanolamine scaffold common to first- and second-generation beta-blockers (propranolol, atenolol, metoprolol) by incorporating two fused 6-fluorochromanol ring systems, producing a conformationally constrained molecule with unprecedented beta-1 selectivity and, as subsequently recognized, vasodilatory properties not attributable to classical beta-receptor pharmacology [2].

3.2 European registration

Nebivolol received its first marketing authorization in 1997 in several European jurisdictions. The compound was registered for the treatment of essential hypertension under the trade names Nebilet (Menarini, multiple European markets), Lobivon (Germany), Temerit (France), and Nodon (select markets). The European indication was subsequently extended in some jurisdictions to include chronic stable heart failure in patients aged 70 years and older on the basis of the SENIORS trial. The compound achieved extensive generic availability across European markets following patent expiration.

3.3 United States development and FDA approval

In 2001, Mylan Laboratories licensed the exclusive United States and Canadian rights to nebivolol from Janssen Pharmaceutica. The compound was subsequently co-developed with Forest Laboratories for the United States market. The clinical development program comprised multiple Phase 3 randomized, double-blind, placebo-controlled trials in patients with mild to moderate hypertension, enrolling more than 2000 patients across a population that included 26 percent Black, 54 percent male, 19 percent elderly, and 8 percent diabetic participants [6]. On December 17, 2007, the FDA approved nebivolol hydrochloride tablets (Bystolic) for the treat-

ment of hypertension. The approved dose range was 5 to 40 mg once daily, with a recommended starting dose of 5 mg. Forest Laboratories was subsequently acquired by Allergan (2014), which merged with AbbVie (2020); Bystolic is currently marketed under the AbbVie portfolio.

3.4 Identification of the nitric oxide mechanism

The vasodilatory properties of nebivolol were recognized early in clinical development from hemodynamic studies demonstrating peripheral resistance reduction atypical for a beta-blocker. The molecular mechanism was elucidated progressively through a series of studies spanning the late 1990s through the 2000s. Dessy et al. (2005) demonstrated that nebivolol produced endothelium-dependent relaxation of coronary microvessels that was abolished in beta-3 adrenergic receptor knockout mice, establishing the beta-3 receptor as the principal mediator [7]. Maffei et al. (2009) confirmed the pathway: l-nebivolol activates beta-3 adrenergic receptors on vascular endothelial cells, increasing intracellular calcium flux, stimulating serine-1177 phosphorylation of eNOS, and producing sustained NO release [8]. Broeders et al. (2000) and Tzemos et al. (2001) independently provided clinical evidence of NO-dependent vasodilation in healthy volunteers and hypertensive patients, respectively [15, 16].

3.5 Identification of biased agonism

Erickson et al. (2013) reported that nebivolol is a GRK/beta-arrestin biased agonist at both beta-1 and beta-2 adrenergic receptors [9]. In HEK293 cells and human umbilical vein endothelial cells expressing beta-1 and beta-2 (but not beta-3) receptors, nebivolol induced rapid receptor internalization, GRK2-dependent phosphorylation, beta-arrestin recruitment, and downstream ERK1/2 activation without measurable changes in cAMP levels. This finding provided a molecular framework for the NO-generating activity in cell types expressing beta-1/beta-2 but not beta-3 receptors, and suggested that the therapeutic profile of nebivolol reflects a composite of classical antagonism, beta-3 agonism, and biased agonism at distinct receptor populations in different vascular beds.

4. Mechanism of Action

Nebivolol is a multi-mechanism cardiovascular agent. Its principal molecular activities, characterized in heterologous expression systems, primary vascular cells, and intact animal models, are highly selective beta-1 adrenergic receptor antagonism; endothelial nitric oxide synthase activation through beta-3 adrenergic receptor agonism; and GRK/beta-arrestin biased agonism at beta-1 and beta-2 adrenergic receptors. These activities converge to produce a hemodynamic profile that combines cardiac rate and contractility reduction with peripheral vasodilation and vascular protection.

4.1 Beta-1 adrenergic receptor antagonism

Nebivolol, through its d-enantiomer (SRRR configuration), is a competitive antagonist at the beta-1 adrenergic receptor with a selectivity ratio of approximately 321:1 (beta-1:beta-2), the highest among clinically marketed beta-blockers [1]. At clinical doses (5 to 10 mg), d-nebivolol produces near-complete occupancy of cardiac beta-1 receptors, reducing heart rate by approximately 8 to 12 beats per minute, decreasing cardiac contractility and myocardial oxygen consumption, and suppressing renin release from juxtaglomerular cells. The beta-1 selectivity is clinically relevant: at therapeutic doses, beta-2 receptor-mediated bronchodilation in airway smooth muscle and beta-2 receptor-mediated hepatic glycogenolysis are substantially preserved, conferring tolerability advantages in patients with reactive airway disease and diabetes mellitus.

4.2 Nitric oxide-dependent vasodilation

The l-enantiomer (RSSS configuration) of nebivolol activates endothelial nitric oxide synthase (eNOS) through stimulation of beta-3 adrenergic receptors on vascular endothelial cells [7, 8]. The signaling cascade proceeds as follows: l-nebivolol binds the beta-3 adrenergic receptor; receptor activation increases intracellular calcium through phospholipase C-dependent mechanisms; calcium-calmodulin binding to eNOS promotes translocation of eNOS from caveolar membrane domains to the cytoplasm; and Akt-mediated phosphorylation of eNOS at serine 1177 produces sustained enzyme activation and NO generation. The released NO diffuses to adjacent

vascular smooth muscle cells, activates soluble guanylyl cyclase, increases cyclic guanosine monophosphate (cGMP), and produces vasorelaxation through protein kinase G-dependent mechanisms [8].

The critical dependence on beta-3 receptors was demonstrated by Dessy et al. (2005), who showed that nebivolol-induced relaxation of isolated coronary microvessels was completely abolished in beta-3 adrenergic receptor knockout mice while preserved in beta-1/beta-2 knockout preparations [7]. The endothelium-dependent nature of the vasodilation was confirmed by mechanical endothelial denudation experiments and by sensitivity to the eNOS inhibitor L-NAME (N(G)-nitro-L-arginine methyl ester).

An additional NO-generating mechanism was identified by Maffei et al. (2007), who demonstrated that nebivolol induces inducible nitric oxide synthase (iNOS) expression in cardiac tissue through a pathway distinct from the eNOS mechanism, contributing to cardioprotective NO signaling in the myocardium during ischemia-reperfusion injury [17].

4.3 GRK/beta-arrestin biased agonism

Erickson et al. (2013) demonstrated that nebivolol functions as a biased agonist at beta-1 and beta-2 adrenergic receptors, activating GRK2-dependent receptor phosphorylation, beta-arrestin 1/2 recruitment, receptor internalization, and downstream ERK1/2 signaling without stimulating classical Gs-protein-coupled adenylyl cyclase activation or cAMP generation [9]. This pharmacological profile is analogous to the biased agonism previously characterized for carvedilol, but nebivolol produces the biased signaling through both beta-1 and beta-2 receptor subtypes rather than predominantly through beta-1. The beta-arrestin-dependent ERK activation is proposed to contribute to cardioprotective and anti-apoptotic signaling in cardiomyocytes and to pro-survival endothelial signaling through transactivation of the epidermal growth factor receptor (EGFR).

4.4 Composite pharmacology and hemodynamic consequences

The composite pharmacology of nebivolol at the recommended clinical dose of 5 mg produces a hemodynamic profile characterized by: (a) heart rate reduction of 8 to 12 beats per minute (beta-1 antagonism); (b) reduction in cardiac output of ap-

proximately 10 to 15 percent (beta-1 antagonism); (c) reduction in systemic vascular resistance of approximately 10 to 20 percent (NO-mediated vasodilation), which partially offsets the cardiac output reduction; and (d) net blood pressure reduction of approximately 11/8 mmHg (systolic/diastolic) [11]. The reduction in peripheral resistance is the distinguishing hemodynamic feature relative to older beta-blockers (atenolol, metoprolol), which either increase or fail to reduce systemic vascular resistance at equivalent blood pressure reductions. This hemodynamic distinction has clinical implications for organ perfusion, endothelial function preservation, central aortic pressure, and metabolic effects (insulin sensitivity, lipid metabolism) that are discussed in subsequent sections.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Nebivolol is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations achieved within 1.5 to 4 hours. The absolute bioavailability displays a striking CYP2D6 polymorphic phenotype: approximately 12 percent in extensive metabolizers (the majority phenotype) and approximately 96 percent in poor metabolizers, reflecting the magnitude of first-pass hepatic CYP2D6-mediated metabolism [13, 14]. Food does not significantly affect the rate or extent of nebivolol absorption; the compound may be administered without regard to meals.

5.2 Distribution

Nebivolol has a large volume of distribution, consistent with extensive tissue partitioning. Plasma protein binding is approximately 98 percent, predominantly to albumin. The compound is lipophilic and crosses the blood-brain barrier, though central nervous system effects are modest at clinical doses. The high protein binding and lipophilicity contribute to the large apparent volume of distribution and the relatively long plasma half-life.

5.3 Metabolism

Nebivolol undergoes extensive hepatic metabolism through multiple cytochrome P450 pathways, with CYP2D6 as the dominant enzyme. The metabolic disposition is enantioselective: CYP2D6 preferentially metabolizes l-nebivolol (the NO-mediating enantiomer), while CYP2C19 preferentially metabolizes d-nebivolol (the beta-blocking enantiomer) [14, 18]. The principal metabolic transformations are aromatic hydroxylation, N-dealkylation, and glucuronidation. Several hydroxylated metabolites (hydroxynebivolol, dihydroxynebivolol) retain beta-adrenergic receptor activ-

ity, though with lower potency than the parent compound. The active metabolites contribute to the overall pharmacodynamic effect, particularly in extensive metabolizers where parent compound exposure is low.

The CYP2D6 polymorphism produces dramatic pharmacokinetic differences. In extensive metabolizers, d-nebivolol and l-nebivolol plasma concentrations achieve steady state within 2 to 3 days of once-daily dosing. In poor metabolizers (approximately 6 to 10 percent of Caucasian populations, approximately 2 percent of East Asian populations), steady-state plasma concentrations of d-nebivolol and l-nebivolol are 10-fold and 15-fold higher, respectively, compared to extensive metabolizers at identical doses [14]. The clinical consequence is that poor metabolizers achieve adequate beta-blockade at lower doses and are at increased risk of dose-dependent adverse effects at standard doses.

Briciu et al. (2014) characterized the pharmacokinetic interaction between nebivolol and the strong CYP2D6 inhibitor paroxetine: co-administration increased nebivolol AUC by 6.1-fold and active metabolite exposure by 5.7-fold, effectively converting extensive metabolizers to a poor metabolizer pharmacokinetic phenotype [19]. Similar magnitude interactions have been demonstrated with fluoxetine (8-fold increase in d-nebivolol AUC) and other strong CYP2D6 inhibitors [20].

5.4 Elimination

The plasma elimination half-life of d-nebivolol is approximately 12 hours in extensive metabolizers and approximately 19 hours in poor metabolizers, supporting once-daily dosing in both phenotypes [13]. Elimination is predominantly through hepatic metabolism; less than 0.5 percent of an administered dose is excreted unchanged in urine. The metabolites are excreted in both urine (approximately 38 percent of dose) and feces (approximately 44 percent of dose). Renal impairment has minimal effect on nebivolol pharmacokinetics at mild to moderate stages; no dose adjustment is required until severe renal impairment (creatinine clearance less than 30 mL/min), at which point a reduced starting dose of 2.5 mg is recommended. Hepatic impairment substantially prolongs elimination, and nebivolol is contraindicated in moderate to severe hepatic impairment.

5.5 Routes of administration

Nebivolol is administered exclusively by the oral route in clinical practice. The marketed formulation (Bystolic) is available as triangular, biconvex tablets in four strengths: 2.5 mg, 5 mg, 10 mg, and 20 mg. Generic nebivolol tablets are available from multiple manufacturers in the same strengths. Parenteral formulations have not been developed for clinical use; research-grade nebivolol may be dissolved in dimethyl sulfoxide for in vitro applications or formulated in aqueous vehicle (with appropriate pH adjustment) for animal pharmacology studies.

5.6 Special populations

Elderly patients (age 65 years and older) do not require routine dose adjustment, though the recommended starting dose is 2.5 mg in this population given the higher prevalence of CYP2D6 poor metabolizer phenotype and concurrent medication use. Pediatric pharmacokinetics have not been formally characterized; the compound is not approved for pediatric use. The SENIORS trial demonstrated safety and efficacy in patients aged 70 years and older with heart failure [10]. Nebivolol is classified as FDA pregnancy category C; animal reproduction studies have demonstrated adverse fetal effects at doses substantially exceeding the human dose, and the compound should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Use in lactation is discouraged owing to limited data on excretion in human milk.

6. Preclinical Pharmacology

6.1 Cardiovascular models

Nebivolol has been extensively characterized in preclinical cardiovascular models. In spontaneously hypertensive rats (SHR), chronic nebivolol administration reduced systolic blood pressure, reversed left ventricular hypertrophy, and improved endothelium-dependent vasorelaxation in a manner dependent on NO signaling, as confirmed by abrogation with L-NAME [21]. In L-NAME hypertensive rats (a model of NO-deficient hypertension), nebivolol partially restored endothelial function and reduced blood pressure, with enantioselective pharmacokinetics demonstrating preferential l-nebivolol distribution to vascular tissue [22].

6.2 Ischemia-reperfusion injury

Nebivolol protects against myocardial ischemia-reperfusion injury through beta-3 adrenergic receptor stimulation and downstream NO signaling. In a rat model of myocardial infarction, nebivolol pretreatment reduced infarct size by approximately 40 percent compared to vehicle, an effect abolished by beta-3 receptor antagonism and by NOS inhibition [23]. The cardioprotective mechanism involves both eNOS activation in coronary endothelium and neuronal NOS (nNOS) activation in cardiomyocytes.

6.3 NLRP3 inflammasome and metabolic inflammation

Nebivolol ameliorates cardiac NLRP3 inflammasome activation in a juvenile-adolescent rat model of diet-induced obesity. Treatment with nebivolol (5 to 10 mg/kg/day) attenuated pro-inflammatory cytokine secretion (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6), reduced NLRP3 inflammasome assembly, and prevented high-fat-diet-induced cardiac lipid accumulation and mitochondrial dysfunction [24]. The anti-inflammatory effect was dose-dependent and was associated with preservation of myocardial mitochondrial function as assessed by respiratory chain complex activity and mitochondrial membrane potential.

6.4 Mitochondrial biogenesis and antioxidant defense

Comparative studies with metoprolol have demonstrated that nebivolol, but not metoprolol, enhances mitochondrial biogenesis and increases expression of antioxidant enzymes (manganese superoxide dismutase, catalase) in angiotensin II-stimulated H9c2 cardiomyoblasts [25]. The mechanism involves upregulation of peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) and nuclear respiratory factor 1 (NRF1), master regulators of mitochondrial biogenesis. These findings suggest that nebivolol provides cellular-level cardioprotection beyond hemodynamic effects that is not shared by conventional beta-1 selective antagonists.

6.5 Anti-inflammatory and anti-atherogenic effects

The anti-inflammatory effects in human coronary smooth muscle cells include suppression of NF-kappaB-dependent transcription, reduction of vascular cell adhesion molecule-1 (VCAM-1) expression, and inhibition of monocyte adhesion, effects consistent with the NO-dependent anti-atherogenic properties [26]. Nebivolol inhibits neointima formation in rodent models of vascular injury and reduces vascular smooth muscle cell proliferation and migration in vitro, suggesting potential utility in preventing atherosclerotic plaque progression.

6.6 Immune modulation

Recent work has demonstrated that nebivolol, through beta-2 adrenergic receptor biased agonism, inhibits Th17 cell differentiation and memory Th17 cell responses through an NF-kappaB-dependent mechanism [27]. This finding extends the anti-inflammatory profile of nebivolol beyond vascular endothelium to adaptive immune regulation and is potentially relevant to autoimmune and chronic inflammatory conditions associated with cardiovascular disease.

6.7 Metabolic neutrality in animal models

In contrast to older beta-blockers (atenolol, metoprolol), nebivolol demonstrates metabolic neutrality in animal models. In rodent models of metabolic syndrome, nebivolol preserved insulin sensitivity and did not worsen glucose homeostasis at blood-pressure-lowering doses, while atenolol worsened insulin resistance under identical conditions [28]. The metabolic advantage is attributed to the NO-mediated

improvement in skeletal muscle blood flow (preserving insulin-mediated glucose uptake) and to the absence of beta-2 receptor blockade (which would impair hepatic glycogenolysis and pancreatic beta-cell insulin secretion).

7. Clinical Evidence Base

7.1 Hypertension

The clinical evidence base for nebivolol in hypertension is extensive. The FDA approval was based on multiple Phase 3 randomized, double-blind, placebo-controlled trials demonstrating dose-dependent reductions in sitting diastolic and systolic blood pressure. At the recommended starting dose of 5 mg once daily, nebivolol reduced sitting diastolic blood pressure by approximately 5 to 7 mmHg and systolic blood pressure by approximately 8 to 12 mmHg compared to placebo [6]. Dose-response analysis demonstrated incremental blood pressure lowering at 10 mg and 20 mg, with diminishing additional benefit above 20 mg.

A meta-analysis of randomized controlled trials confirmed the antihypertensive efficacy of nebivolol across diverse patient populations and demonstrated comparable blood pressure reductions to other beta-blockers and to other antihypertensive drug classes (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin receptor blockers) [11]. A 2020 meta-analysis reported pooled systolic blood pressure reductions of 11.0 mmHg (95 percent CI 8.7 to 13.3) and diastolic reductions of 8.1 mmHg (95 percent CI 6.4 to 9.8) compared to placebo [12].

Comparative trials against atenolol (50 mg) have demonstrated equivalent blood pressure reduction with significantly fewer complaints of fatigue and sexual dysfunction in the nebivolol group [29]. Comparative trials against metoprolol have demonstrated similar antihypertensive efficacy with superior effects of nebivolol on central aortic pressure, arterial stiffness, and endothelial function [30]. A multi-center cohort study published in 2025 comparing nebivolol with other beta-blockers in hypertensive patients demonstrated significantly greater blood pressure reductions with nebivolol (11.0 mmHg systolic) compared to carvedilol over a mean follow-up of 4.5 years [31].

7.2 Heart failure

The SENIORS trial (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure) is the pivotal heart failure outcomes trial [10]. The study randomized 2128 patients aged 70 years or older with

clinical heart failure (irrespective of ejection fraction; mean age 76.1 years; 37 percent women) to nebivolol (titrated to a target dose of 10 mg once daily) or placebo. After a mean follow-up of 21 months, the primary composite endpoint of all-cause mortality or cardiovascular hospital admission occurred in 332 patients (31.1 percent) on nebivolol versus 375 (35.3 percent) on placebo (hazard ratio 0.86, 95 percent CI 0.74 to 0.99, $P = 0.039$). All-cause mortality was 15.8 percent on nebivolol versus 18.1 percent on placebo (HR 0.88, 95 percent CI 0.71 to 1.08, $P = 0.21$), a trend that did not reach statistical significance.

The SENIORS echocardiographic substudy demonstrated that nebivolol improved left ventricular ejection fraction, reduced left ventricular end-systolic and end-diastolic volumes, and improved markers of diastolic function in the treated group compared to placebo [32]. Subgroup analysis demonstrated that the effect of nebivolol on the primary outcome was consistent regardless of age, sex, or baseline ejection fraction, including patients with preserved ejection fraction (LVEF greater than 35 percent), a population in which other beta-blockers have not demonstrated benefit in dedicated outcomes trials.

The SENIORS trial with impaired renal function substudy demonstrated that nebivolol's benefits were preserved in patients with reduced estimated glomerular filtration rate, with no excess of renal adverse events [33].

A limitation of the SENIORS trial is the absence of a direct comparison with other beta-blockers (bisoprolol, carvedilol, metoprolol succinate) that have demonstrated mortality reduction in younger heart failure populations. The effect size in SENIORS (HR 0.86) was numerically smaller than the effect sizes reported for bisoprolol in CIBIS-II (HR 0.66), carvedilol in COPERNICUS (HR 0.65), and metoprolol succinate in MERIT-HF (HR 0.66), though direct cross-trial comparison is limited by differences in patient age, ejection fraction inclusion criteria, and comparator arms.

7.3 Endothelial function and vascular health

Multiple clinical studies have demonstrated that nebivolol improves endothelial function as measured by flow-mediated dilation of the brachial artery, a validated surrogate for NO bioavailability and vascular health [16]. In hypertensive patients, nebivolol increased flow-mediated dilation by approximately 4 to 6 percentage points compared to baseline, while atenolol produced no significant improvement

at equivalent blood pressure reductions [34]. The improvement in endothelial function is attributed to the NO-releasing mechanism and has been proposed as a contributor to long-term vascular protection beyond blood pressure lowering.

7.4 Metabolic effects

Clinical trials have consistently demonstrated metabolic neutrality of nebivolol in contrast to older beta-blockers. In the hypertension clinical program, nebivolol did not worsen fasting glucose, hemoglobin A1c, total cholesterol, LDL cholesterol, or triglycerides compared to placebo [6]. A dedicated study in diabetic hypertensive patients demonstrated no worsening of glycemic control with nebivolol compared to significant deterioration with metoprolol [35]. The metabolic neutrality is attributed to the preservation of beta-2 mediated metabolic pathways (by virtue of beta-1 selectivity) and to the NO-mediated improvement in insulin-mediated glucose uptake in skeletal muscle.

7.5 Sexual function

Beta-blocker-associated sexual dysfunction (erectile dysfunction in men, reduced libido in both sexes) is a clinically significant limitation of older agents. Multiple controlled trials and meta-analyses have demonstrated that nebivolol does not produce clinically significant sexual dysfunction at therapeutic doses. A controlled comparison with atenolol demonstrated that the incidence of sexual dysfunction complaints was 0.2 percent with nebivolol versus 8 percent with atenolol, a difference attributable to the NO-mediated mechanism (NO is the principal mediator of penile erection) [29, 36]. A prospective randomized crossover trial comparing nebivolol with metoprolol in men undergoing coronary artery bypass surgery demonstrated preservation of erectile function with nebivolol and significant impairment with metoprolol [37].

8. Sourcing and Quality Verification

Pharmaceutical-grade nebivolol (Bystolic brand or licensed generics) is the highest quality source for research applications requiring regulatory equivalence to clinical material. The pharmaceutical-grade material is supplied as 2.5, 5, 10, or 20 mg oral tablets in the marketed formulations and is available by prescription in the United States, the European Union, and multiple other jurisdictions. Generic nebivolol tablets are widely available and are bioequivalent to the branded product by regulatory requirement.

Research-grade nebivolol is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich/Merck, Cayman Chemical, MedChemExpress, Selleckchem, Tocris, Toronto Research Chemicals, others) at greater than 98 percent purity by HPLC. Supply is in milligram to gram quantities as either the free base or the hydrochloride salt. Pricing is moderate, in the range of \$50 to \$300 per gram of research-grade material. Individual enantiomers (d-nebivolol and l-nebivolol) are available from select specialty suppliers for enantioselective pharmacology research.

Investigators should confirm compound identity, purity, and enantiomeric composition on every research-grade lot through:

- High-performance liquid chromatography area-percent purity (target greater than 98 percent)
- Mass spectrometry confirmation of molecular weight (406.18 plus or minus 0.01 for the protonated free base $[M+H]^+$)
- Chiral HPLC confirmation of the racemic 1:1 enantiomeric composition (or single enantiomer purity if specific enantiomer is required)
- Nuclear magnetic resonance spectroscopy (1H and ^{19}F NMR) for structural confirmation
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade nebivolol market is well established; lot-to-lot variability is uncommon but analytical confirmation is appropriate for mech-

anistic studies where precise dose-response characterization is critical.

9. Reconstitution and Handling

Nebivolol hydrochloride is sparingly soluble in water (approximately 1 mg/mL at neutral pH) and freely soluble in dimethyl sulfoxide (DMSO; approximately 50 mg/mL), methanol, and acidified aqueous solutions. For in vitro research applications, stock solutions are typically prepared at 10 to 50 mM in DMSO and diluted to working concentrations in cell culture media or buffer. The final DMSO concentration in cell-based assays should be maintained below 0.1 percent (v/v) to avoid solvent cytotoxicity.

For animal pharmacology studies, nebivolol is administered orally (gavage or diet admixture) at doses typically ranging from 1 to 10 mg/kg/day in rodents. Aqueous formulations may be prepared by dissolution of the hydrochloride salt in 0.5 percent carboxymethylcellulose or similar vehicle at mildly acidic pH (pH 3 to 5). Parenteral formulations (intraperitoneal, subcutaneous) are prepared in DMSO/saline or DMSO/polyethylene glycol 400 vehicles at concentrations appropriate to the injection volume.

For clinical-research applications, pharmaceutical-grade tablets are the standard dosage form. Tablet manipulation (crushing, splitting) for dose adjustment is feasible given the immediate-release formulation; the tablets are not coated with an enteric or sustained-release barrier.

Storage conditions: pharmaceutical-grade tablets should be stored at 20 to 25 degrees Celsius (68 to 77 degrees Fahrenheit), with excursions permitted to 15 to 30 degrees Celsius. Research-grade powder should be stored at minus 20 degrees Celsius for long-term storage, protected from moisture and light. DMSO stock solutions are stable at minus 20 degrees Celsius for at least 6 months; repeated freeze-thaw cycles should be avoided through single-use aliquoting.

10. Stack Interactions and Combinations

Nebivolol interacts with several drug classes through its CYP2D6-mediated metabolism and through its pharmacodynamic activity on cardiac conduction, vascular tone, and autonomic regulation. Investigators and clinicians should consider the following interactions:

CYP2D6 inhibitors: Strong CYP2D6 inhibitors (fluoxetine, paroxetine, quinidine, bupropion, terbinafine) dramatically increase nebivolol exposure (6- to 8-fold AUC increase) and can convert extensive metabolizers to a poor-metabolizer phenotype [19, 20]. Co-administration necessitates dose reduction to 2.5 mg or lower and enhanced monitoring for bradycardia and hypotension. Moderate CYP2D6 inhibitors (sertraline, duloxetine, diphenhydramine) produce smaller but clinically relevant increases in nebivolol exposure. Case reports of complete heart block have been documented following addition of paroxetine or fluoxetine to stable nebivolol therapy.

CYP2D6 inducers: Rifampin, carbamazepine, and phenytoin (through general CYP induction including CYP2D6) may reduce nebivolol exposure, potentially compromising antihypertensive efficacy.

Other beta-blockers: Concurrent administration with another beta-blocker is pharmacologically redundant and increases the risk of severe bradycardia, atrioventricular block, and heart failure decompensation. The combination is not recommended.

Calcium channel blockers (non-dihydropyridine): Concurrent verapamil or diltiazem with nebivolol produces additive negative chronotropic and dromotropic effects, increasing the risk of severe bradycardia and high-degree atrioventricular block. The combination requires close monitoring. Dihydropyridine calcium channel blockers (amlodipine, nifedipine) may be combined with nebivolol for additive blood pressure lowering with manageable risk.

Antiarrhythmics: Class I antiarrhythmics (disopyramide, quinidine, flecainide, propafenone) may produce additive cardiac conduction depression. Quinidine and propafenone are also CYP2D6 inhibitors, adding a pharmacokinetic interaction. Amiodarone combined with nebivolol increases the risk of bradycardia and hypotension.

Digoxin: Concurrent digoxin and nebivolol produce additive atrioventricular nodal depression. Digoxin levels should be monitored, and heart rate surveillance is appropriate.

Clonidine: Concurrent clonidine and beta-blocker therapy increases the risk of rebound hypertension upon clonidine withdrawal. If discontinuation of both agents is required, nebivolol should be tapered first, followed by clonidine.

Anesthetic agents: General anesthetics (halothane, enflurane, isoflurane) may potentiate the myocardial depressant effects of nebivolol. Continuation of beta-blocker therapy through the perioperative period is generally recommended to avoid withdrawal tachycardia, but anesthetic management should account for the potential for additive cardiac depression.

Antidiabetic agents: Nebivolol may mask the symptoms of hypoglycemia (tachycardia, tremor) in patients receiving insulin or oral hypoglycemic agents. The metabolic neutrality of nebivolol reduces but does not eliminate this concern. Blood glucose monitoring is appropriate in diabetic patients.

NSAIDs: Nonsteroidal anti-inflammatory drugs may attenuate the antihypertensive effect of nebivolol through inhibition of renal prostaglandin synthesis and sodium retention.

Sildenafil and other PDE5 inhibitors: Concurrent PDE5 inhibitors and nebivolol may produce additive hypotension. The NO-mediated vasodilatory mechanism of nebivolol is pharmacologically synergistic with the cGMP-preserving mechanism of PDE5 inhibitors. The combination is not contraindicated but warrants blood pressure monitoring.

11. Adverse Events and Safety

11.1 Common adverse events

The adverse event profile of nebivolol in controlled clinical trials is notable for its similarity to placebo. At the recommended starting dose of 5 mg daily, the following adverse events were reported at rates exceeding placebo by 1 percent or more [6]:

- Headache (6 to 9 percent, versus 6 to 7 percent placebo)
- Fatigue (1 to 5 percent, versus 1 to 2 percent placebo)
- Dizziness (2 to 4 percent, versus 2 to 3 percent placebo)
- Diarrhea (2 to 3 percent, versus 1 to 2 percent placebo)
- Nausea (1 to 3 percent, versus 1 to 2 percent placebo)
- Bradycardia (less than 1 percent, versus less than 1 percent placebo; dose-dependent)

The adverse event rates are consistently lower than those reported for atenolol, metoprolol, and propranolol at equivalent blood pressure reductions, reflecting the beta-1 selectivity and NO-mediated vasodilation that spare beta-2 mediated pathways and preserve peripheral perfusion.

11.2 Sexual dysfunction

Sexual dysfunction (erectile dysfunction, decreased libido) is reported at rates of 0.2 percent or less with nebivolol, compared to 0.0 percent with placebo, and compared to 5 to 15 percent with older beta-blockers [29, 36]. The preservation of sexual function is attributed to the NO-releasing mechanism, as NO is the principal mediator of corpus cavernosum smooth muscle relaxation and penile erection.

11.3 Metabolic adverse effects

Nebivolol does not produce clinically significant worsening of glucose metabolism, insulin sensitivity, total cholesterol, LDL cholesterol, or triglycerides at therapeutic doses [35]. This metabolic neutrality is distinct from atenolol and metoprolol,

which are associated with new-onset diabetes (odds ratio approximately 1.2 to 1.4 compared to placebo) and with worsening of lipid profiles in long-term clinical trials.

11.4 Serious adverse events

Rare and serious adverse events include:

- Severe bradycardia (heart rate less than 50 beats per minute) requiring dose reduction or discontinuation, particularly in patients with underlying conduction disease or concurrent use of rate-limiting agents
- Heart block (first-degree: uncommon; second- or third-degree: rare, reported in post-marketing surveillance and in combination with CYP2D6 inhibitors)
- Acute heart failure decompensation upon initiation in inadequately compensated patients (a class effect of beta-blockers; nebivolol should be initiated at low dose with gradual up titration)
- Bronchospasm in patients with asthma or severe reactive airway disease (rare at therapeutic doses given beta-1 selectivity, but beta-1 selectivity is relative and not absolute; nebivolol is contraindicated in severe asthma)
- Hepatic injury (rare case reports; not established as a class effect)

11.5 Withdrawal

Abrupt discontinuation of nebivolol (as with all beta-blockers) may precipitate rebound tachycardia, hypertension, and, in patients with coronary artery disease, angina exacerbation or myocardial infarction. Gradual dose taper over 1 to 2 weeks is recommended upon discontinuation.

11.6 Contraindications

The compound is contraindicated in: severe bradycardia (heart rate less than 60 beats per minute at rest); greater than first-degree heart block (without a functioning pacemaker); decompensated heart failure requiring intravenous inotropic therapy; cardiogenic shock; sick sinus syndrome (without a pacemaker); severe hepatic impairment (Child-Pugh B or C); and known hypersensitivity to nebivolol or excipients.

11.7 Pregnancy and lactation

Animal reproduction studies have demonstrated adverse fetal effects at doses substantially exceeding the human therapeutic dose. No adequate and well-controlled human studies exist. The compound is classified as FDA pregnancy category C. Use during pregnancy is recommended only when the potential benefit justifies the potential risk to the fetus. Use in lactation is discouraged owing to limited data on excretion in human milk.

12. Comparative Assessment

This section presents a structured comparative assessment of five alternative beta-blockers against nebivolol, evaluated on five competency standards: novelty of mechanism, effect size (blood pressure reduction and outcomes), tolerability profile, metabolic neutrality, and overall validation. The five comparators were selected as the principal beta-blockers in clinical use for hypertension and heart failure, representing first-, second-, and third-generation agents.

12.1 Metoprolol (Lopressor, Toprol-XL)

Mechanism: Second-generation beta-1 selective adrenergic receptor antagonist without intrinsic sympathomimetic activity. No vasodilatory properties. No NO-releasing mechanism.

Novelty: Low. Conventional beta-1 selective antagonism within the aryloxypropanolamine scaffold. No additional mechanisms.

Effect size: Metoprolol succinate (extended-release) reduced all-cause mortality by 34 percent in MERIT-HF (HR 0.66, P less than 0.001) in patients with symptomatic heart failure and reduced ejection fraction [38]. Blood pressure reduction in hypertension is comparable to nebivolol at equivalent doses (approximately 10 to 13 mmHg systolic). The MERIT-HF effect size is substantially larger than SENIORS, though the populations are not directly comparable (MERIT-HF: mean age 64, LVEF less than 40 percent; SENIORS: mean age 76, all ejection fractions).

Tolerability profile: Inferior to nebivolol. Fatigue is reported in 10 to 15 percent of patients. Sexual dysfunction is reported in 5 to 10 percent. Cold extremities and exercise intolerance are common at higher doses. The adverse event profile reflects the absence of vasodilation and the higher beta-2 receptor occupancy at clinical doses.

Metabolic neutrality: Inferior to nebivolol. Metoprolol worsens insulin sensitivity, increases the risk of new-onset diabetes (OR approximately 1.2 to 1.4 compared to placebo in long-term trials), and modestly worsens lipid profiles (increased triglycerides, decreased HDL cholesterol).

Overall validation: High. Metoprolol succinate has Level I evidence for mortality reduction in heart failure with reduced ejection fraction (MERIT-HF) and is a guideline-recommended first-line heart failure therapy. Antihypertensive efficacy is well established. The principal limitation relative to nebivolol is the inferior tolerability and metabolic profile.

Comparison to nebivolol: Metoprolol has stronger outcomes evidence in heart failure with reduced ejection fraction but inferior tolerability, metabolic effects, and endothelial function effects. The choice between agents is influenced by the clinical context: metoprolol succinate is preferred in younger patients with systolic heart failure where mortality reduction is the primary goal; nebivolol may be preferred in elderly patients, in patients with preserved ejection fraction, and in patients where metabolic effects and sexual function are relevant concerns.

12.2 Bisoprolol (Zebeta, Concor)

Mechanism: Second-generation beta-1 selective adrenergic receptor antagonist. High beta-1 selectivity (approximately 120:1 beta-1:beta-2), the second highest among marketed beta-blockers after nebivolol. No vasodilatory properties. No NO-releasing mechanism.

Novelty: Low. Conventional beta-1 selective antagonism.

Effect size: Bisoprolol reduced all-cause mortality by 34 percent in CIBIS-II (HR 0.66, P less than 0.001) in patients with symptomatic heart failure and LVEF 35 percent or less [39]. Blood pressure reduction in hypertension is comparable to nebivolol. A Korean cohort comparison of nebivolol versus bisoprolol in hypertensive patients showed numerically lower all-cause mortality with nebivolol (9.8 percent versus 11.5 percent), cardiovascular mortality (5.4 percent versus 7.0 percent), and cardiovascular hospitalization (9.8 percent versus 12.1 percent), though differences did not reach statistical significance [40].

Tolerability profile: Intermediate. Superior to metoprolol and atenolol owing to higher beta-1 selectivity, but inferior to nebivolol owing to the absence of vasodilation. Fatigue and cold extremities are less frequent than with metoprolol but more frequent than with nebivolol.

Metabolic neutrality: Intermediate. Bisoprolol produces less metabolic derangement than atenolol but is not metabolically neutral. Some worsening of glucose tolerance has been reported in long-term studies.

Overall validation: High. CIBIS-II provides Level I evidence for mortality reduction in heart failure with reduced ejection fraction. Bisoprolol is guideline-recommended for heart failure and hypertension in multiple international guidelines.

Comparison to nebivolol: Bisoprolol shares high beta-1 selectivity with nebivolol but lacks the NO-mediated vasodilation, the metabolic neutrality, and the endothelial function benefits. Heart failure outcomes evidence is stronger for bisoprolol (CIBIS-II) than for nebivolol (SENIORS), though in different populations. The two agents are reasonable alternatives with the choice depending on clinical priorities.

12.3 Carvedilol (Coreg)

Mechanism: Third-generation non-selective beta-blocker (beta-1, beta-2) with alpha-1 adrenergic receptor antagonism, antioxidant properties, and beta-arrestin biased agonism at beta-1 receptors. The alpha-1 antagonism provides vasodilation through a mechanism distinct from nebivolol's NO pathway.

Novelty: Moderate. The combination of non-selective beta-blockade, alpha-1 antagonism, and biased agonism is pharmacologically distinct from nebivolol. Both agents are classified as third-generation beta-blockers but achieve vasodilation through different mechanisms (alpha-1 blockade versus NO release).

Effect size: Carvedilol reduced all-cause mortality by 35 percent in COPENHAGEN (HR 0.65, P = 0.0014) in severe heart failure [41] and by 65 percent in the US Carvedilol Heart Failure Trials Program [42]. Blood pressure reduction in hypertension is comparable to nebivolol (approximately 10 to 14 mmHg systolic). The heart failure mortality reduction is the largest among beta-blockers.

Tolerability profile: Inferior to nebivolol. The non-selective beta-blockade produces beta-2 mediated adverse effects (bronchospasm risk, metabolic derangement). Alpha-1 antagonism produces orthostatic hypotension and dizziness, particularly during up titration. Fatigue rates are higher than with nebivolol.

Metabolic neutrality: Mixed. Carvedilol demonstrates better metabolic effects than atenolol and metoprolol (attributed to alpha-1 antagonism improving insulin sensitivity), but inferior to nebivolol. Some studies report modest worsening of glycemic control in diabetic patients.

Overall validation: Very high. Carvedilol has the strongest mortality evidence among beta-blockers across multiple heart failure trials (US Carvedilol, COPENICUS, COMET). It is the most extensively validated third-generation beta-blocker.

Comparison to nebivolol: Carvedilol has stronger heart failure outcomes evidence but inferior tolerability and beta-1 selectivity. Nebivolol has superior metabolic neutrality, sexual function preservation, and endothelial function effects. The two third-generation agents represent different design strategies for vasodilatory beta-blockade: carvedilol achieves vasodilation through alpha-1 antagonism at the cost of non-selective beta-blockade, while nebivolol achieves vasodilation through NO release while preserving beta-1 selectivity.

12.4 Atenolol (Tenormin)

Mechanism: Second-generation beta-1 selective adrenergic receptor antagonist without intrinsic sympathomimetic activity. Hydrophilic, with limited central nervous system penetration. No vasodilatory properties.

Novelty: Low. The archetypal second-generation cardioselective beta-blocker.

Effect size: Atenolol has extensive antihypertensive efficacy data but limited outcomes evidence. The LIFE trial (losartan versus atenolol in hypertension with left ventricular hypertrophy) demonstrated inferior cardiovascular outcomes with atenolol compared to losartan despite equivalent blood pressure reduction, raising questions about the intrinsic vascular protection provided by atenolol [43]. Blood pressure reduction is comparable to nebivolol at standard doses.

Tolerability profile: Inferior to nebivolol. Fatigue (15 to 25 percent), cold extremities (10 to 15 percent), and sexual dysfunction (5 to 15 percent) are substantially more frequent than with nebivolol. The hydrophilic nature limits some central nervous system adverse effects (depression, nightmares) that are more common with lipophilic agents.

Metabolic neutrality: Poor. Atenolol consistently worsens glucose tolerance, increases new-onset diabetes risk, and produces adverse lipid changes in long-term trials. The ASCOT-BPLA trial demonstrated significantly higher rates of new-onset diabetes with atenolol-based treatment compared to amlodipine-based treatment [44].

Overall validation: Moderate. Atenolol has extensive antihypertensive efficacy data but negative or neutral outcomes evidence in recent large trials (LIFE, ASCOT-BPLA). Current guidelines have de-emphasized atenolol as a first-line antihypertensive owing to inferior outcomes compared to other classes and to other beta-blockers.

Comparison to nebivolol: Nebivolol is superior to atenolol on every competency standard evaluated: superior tolerability, superior metabolic neutrality, superior endothelial function effects, and equivalent or superior blood pressure reduction. Atenolol serves as the historical reference comparator that highlights the clinical advantages of third-generation beta-blocker pharmacology.

12.5 Propranolol (Inderal)

Mechanism: First-generation non-selective beta-blocker (beta-1 and beta-2) without intrinsic sympathomimetic activity. Highly lipophilic with extensive central nervous system penetration. No vasodilatory properties; increases peripheral vascular resistance.

Novelty: Historical. Propranolol was the first clinically successful beta-blocker (James Black, 1964, Nobel Prize 1988) and defined the therapeutic class. No additional mechanisms beyond non-selective beta-blockade.

Effect size: Propranolol has demonstrated efficacy in hypertension, angina pectoris, essential tremor, migraine prophylaxis, and performance anxiety. Blood pressure reduction is comparable to other beta-blockers. Cardiovascular outcomes evidence is limited to earlier-era trials that do not meet contemporary trial design standards.

Tolerability profile: Inferior to nebivolol. Non-selective beta-blockade produces the full spectrum of beta-2 mediated adverse effects: bronchospasm, cold extremities, exercise intolerance, and metabolic derangement. Central nervous system penetration produces depression, nightmares, and fatigue at rates substantially higher than with nebivolol. Sexual dysfunction rates are 10 to 20 percent.

Metabolic neutrality: Poor. Non-selective beta-blockade worsens insulin sensitivity, glucose tolerance, and lipid profiles to a greater degree than selective beta-1 antagonists. Propranolol masks hypoglycemia symptoms and is used cautiously in diabetes.

Overall validation: High for historical importance and for non-cardiovascular indications (essential tremor, migraine, performance anxiety). Low for contemporary cardiovascular practice, where it has been largely replaced by selective agents.

Comparison to nebivolol: Nebivolol is pharmacologically and clinically superior for cardiovascular indications. Propranolol retains utility for non-cardiovascular indications (essential tremor, migraine prophylaxis, performance anxiety) where central nervous system penetration and non-selectivity are therapeutically advantageous.

12.6 Comparator summary

The five comparators span the three generations of beta-blocker development and illustrate the progressive improvement in selectivity, tolerability, and ancillary properties that defines the class trajectory. **Metoprolol** and **bisoprolol** represent second-generation beta-1 selective agents with strong heart failure mortality evidence (MERIT-HF, CIBIS-II) but limited vasodilatory and metabolic benefits. **Carvedilol** represents the alternative third-generation approach (alpha-1 antagonism for vasodilation, non-selective beta-blockade) with the strongest heart failure mortality evidence but inferior beta-1 selectivity and tolerability. **Atenolol** is the historical cardioselective reference with the poorest contemporary outcomes evidence and the clearest demonstration of the limitations of beta-blockade without vasodilation. **Propranolol** is the founding non-selective agent with residual utility in non-cardiovascular indications.

Nebivolol occupies a unique position in this landscape: it is the only beta-blocker with endothelial NO-dependent vasodilation, the agent with the highest beta-1 selectivity, and the agent with the most favorable metabolic and sexual function profile. Its heart failure outcomes evidence (SENIORS) is less robust than bisoprolol, metoprolol, or carvedilol, principally because SENIORS enrolled an older population with mixed ejection fractions and produced a smaller effect size. The clinical positioning of nebivolol is therefore as the preferred beta-blocker when tolerability, metabolic neutrality, endothelial function, and sexual function are prioritized, and as an important alternative in elderly heart failure patients and in patients with preserved ejection fraction where conventional beta-blockers lack outcomes evidence.

13. References

1. Bristow MR, Nelson P, Minobe W, Johnson C. Characterization of beta1-selective properties of nebivolol. *J Am Coll Cardiol*. 2005;45(3 Suppl A):A217.
2. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. *J Cardiovasc Pharmacol*. 1988;11(5):552-563.
3. Freepatentsonline.com. Process for the synthesis of intermediates of nebivolol. US Patent 10,392,361. Menarini International Operations Luxembourg S.A.
4. Kapoor M, Gupta MN. Synthesis of enantiopure beta-blocker (+)-nebivolol by enzyme catalyzed asymmetrization reaction. *Top Catal*. 2025;68:DOI 10.1007/s11244-025-02059-2.
5. Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. *J Am Coll Cardiol*. 2009;54(16):1491-1499.
6. Bystolic (nebivolol) tablets, for oral use. Full prescribing information. Forest Laboratories, Inc. FDA-approved label, December 17, 2007. Revised 2011.
7. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. *Circulation*. 2005;112(8):1198-1205.
8. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. *Ther Adv Cardiovasc Dis*. 2009;3(4):317-327.
9. Erickson CE, Gul R, Bhatt CP, et al. The beta-blocker nebivolol is a GRK/beta-arrestin biased agonist. *PLoS One*. 2013;8(8):e71980.
10. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J*. 2005;26(3):215-225.
11. Van Bortel LM, Fici F, Struijker-Boudier HA. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. *Am J Cardiovasc Drugs*. 2008;8(1):35-44.

12. Gao Y, Wang Z, Zhang Y, et al. Efficacy and safety of nebivolol in hypertensive patients: a meta-analysis of randomized controlled trials. *Front Pharmacol*. 2020;11:554735.
13. Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. *Eur J Clin Pharmacol*. 1997;51(6):493-498.
14. Lefebvre J, Poirier L, Bhatt DL, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. *Br J Clin Pharmacol*. 2015;80(5):1021-1028.
15. Broeders MG, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. *Circulation*. 2000;102(6):677-684.
16. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. *Circulation*. 2001;104(5):511-514.
17. Maffei A, Di Pardo A, Carangi R, et al. Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation. *Hypertension*. 2007;50(4):652-656.
18. Bathala MS, Masumder H, Engstrom RG, et al. Pharmacokinetics, biotransformation, and mass balance of nebivolol following a single oral dose of ¹⁴C-nebivolol to healthy human volunteers. *Drug Metab Dispos*. 2008;36(8):1578-1586.
19. Briciu C, Neag M, Muntean D, et al. A pharmacokinetic drug interaction study between nebivolol and paroxetine in healthy volunteers. *J Clin Pharm Ther*. 2014;39(5):535-540.
20. Sager JE, Price LS, Isoherranen N. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. *J Clin Pharmacol*. 2010;50(9 Suppl):188S.
21. Toblli JE, DiGennaro F, Giani JF, et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. *Vasc Health Risk Manag*. 2012;8:151-160.

22. Takata Y, Hirayama Y, Kiyomi S, et al. Enantioselective pharmacokinetics and cardiovascular effects of nebivolol in L-NAME hypertensive rats. *Hypertens Res.* 2014;37(2):108-115.
23. Sorrentino SA, Doerries C, Manes C, et al. Nebivolol protects against myocardial infarction injury via stimulation of beta 3-adrenergic receptors and nitric oxide signaling. *PLoS One.* 2014;9(5):e98179.
24. Jimenez-Gonzalez S, Marin-Royo G, Jurado-Lopez R, et al. Nebivolol ameliorates cardiac NLRP3 inflammasome activation in a juvenile-adolescent animal model of diet-induced obesity. *Sci Rep.* 2016;6:34326.
25. El-Sayed NS, Eissa Ahmed AA, El-Demerdash E. Differential effects of beta-blockers nebivolol and metoprolol on mitochondrial biogenesis and antioxidant defense in angiotensin II-induced pathology in H9c2 cardiomyoblasts. *BMC Pharmacol Toxicol.* 2025;26:DOI 10.1186/s40360-025-00970-8.
26. Wolf SC, Sauter G, Preyer M, et al. The anti-inflammatory effects of nebivolol in human coronary smooth muscle cells. *Int J Cardiol.* 2008;124(1):92-99.
27. Zhan Y, Wu L, Shi X, et al. The beta2-adrenergic biased agonist nebivolol inhibits the development of Th17 and the response of memory Th17 cells in an NF-kappaB-dependent manner. *Front Immunol.* 2024;15:1446424.
28. Celik T, Iyisoy A, Kursaklioglu H, et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. *J Hypertens.* 2006;24(3):591-596.
29. Doumas M, Tsakiris A, Douma S, et al. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. *Int J Clin Pract.* 2006;60(Suppl 152):42-46.
30. Kampus P, Serg M, Kals J, et al. The effect of low-dose carvedilol, nebivolol, and metoprolol on central arterial pressure and its determinants: a randomized clinical trial. *J Am Heart Assoc.* 2021;10(6):e019414.
31. Kim JH, Lee SY, Park HY, et al. Comparative effectiveness and outcomes of nebivolol versus other beta blockers in patients with hypertension: a multicenter cohort study. *J Am Heart Assoc.* 2025;14:e044910.
32. Ghio S, Magrini G, Serio A, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. *Eur Heart J.* 2006;27(5):562-568.

33. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. *Eur J Heart Fail.* 2009;11(9):872-880.
34. Mahmud A, Feely J. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. *Am J Hypertens.* 2008;21(6):663-667.
35. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. *J Hum Hypertens.* 1997;11(11):753-757.
36. Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide, erectile dysfunction and beta-blocker treatment: the nebivolol/beta-blocker comparison trial. *Cardiovasc Drugs Ther.* 2007;21(1):77-82.
37. Ertugrul DT, Yildirim B, Yazici G, et al. Nebivolol protects erectile functions compared to metoprolol in hypertensive men. *Eur J Vasc Endovasc Surg.* 2022;65(2):234-240.
38. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet.* 1999;353(9169):2001-2007.
39. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet.* 1999;353(9146):9-13.
40. Kim SH, Park JH, Lee JJ, et al. Comparison of nebivolol and bisoprolol for cardiovascular mortality in hypertensive patients. *J Am Heart Assoc.* 2020;9(1):e014564.
41. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. *Circulation.* 2002;106(17):2194-2199.
42. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Trials Program. *N Engl J Med.* 1996;334(21):1349-1355.
43. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. *Lancet.* 2002;359(9311):995-

1003.

44. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*. 2005;366(9489):895-906.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Nebivolol hydrochloride tablets (Bystolic) are approved by the United States Food and Drug Administration for the treatment of hypertension. The compound is registered in multiple jurisdictions for hypertension and, in some European markets, for chronic heart failure in elderly patients. Investigators should consult their local regulatory authority and institutional review board before any human research application.